It won't be the only focus
From the company update on 20 august:
"Exploit the best opportunities from its current biotechnology intellectual property, specifically the
“Oraline” series.
Add additional biotechnology assets and potentially attract high calibre, experienced biotechnology
talent to the Company in the process."